162 related articles for article (PubMed ID: 37466744)
1. Targeting TRIM24 promotes neuroblastoma differentiation and decreases tumorigenicity via LSD1/CoREST complex.
Shi Q; Yu B; Zhang Y; Yang Y; Xu C; Zhang M; Chen G; Luo F; Sun B; Yang R; Li Y; Feng H
Cell Oncol (Dordr); 2023 Dec; 46(6):1763-1775. PubMed ID: 37466744
[TBL] [Abstract][Full Text] [Related]
2. MYT1 attenuates neuroblastoma cell differentiation by interacting with the LSD1/CoREST complex.
Chen K; Cai Y; Cheng C; Zhang J; Lv F; Xu G; Duan P; Wu Y; Wu Z
Oncogene; 2020 May; 39(21):4212-4226. PubMed ID: 32251364
[TBL] [Abstract][Full Text] [Related]
3. The combined effect of retinoic acid and LSD1 siRNA inhibition on cell death in the human neuroblastoma cell line SH-SY5Y.
Xu G; Xiao Y; Hu J; Xing L; Zhao O; Wu Y
Cell Physiol Biochem; 2013; 31(6):854-62. PubMed ID: 23816987
[TBL] [Abstract][Full Text] [Related]
4. Unfavorable neuroblastoma prognostic factor NLRR2 inhibits cell differentiation by transcriptional induction through JNK pathway.
Sheikh A; Takatori A; Hossain MS; Hasan MK; Tagawa M; Nagase H; Nakagawara A
Cancer Sci; 2016 Sep; 107(9):1223-32. PubMed ID: 27357360
[TBL] [Abstract][Full Text] [Related]
5. LSD1 mediates MYCN control of epithelial-mesenchymal transition through silencing of metastatic suppressor NDRG1 gene.
Ambrosio S; Amente S; Saccà CD; Capasso M; Calogero RA; Lania L; Majello B
Oncotarget; 2017 Jan; 8(3):3854-3869. PubMed ID: 27894074
[TBL] [Abstract][Full Text] [Related]
6. The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma.
Lampis S; Raieli S; Montemurro L; Bartolucci D; Amadesi C; Bortolotti S; Angelucci S; Scardovi AL; Nieddu G; Cerisoli L; Paganelli F; Valente S; Fischer M; Martelli AM; Pasquinelli G; Pession A; Hrelia P; Tonelli R
J Exp Clin Cancer Res; 2022 Apr; 41(1):160. PubMed ID: 35490242
[TBL] [Abstract][Full Text] [Related]
7. CFC1 is a cancer stemness-regulating factor in neuroblastoma.
Chikaraishi K; Takenobu H; Sugino RP; Mukae K; Akter J; Haruta M; Kurosumi M; Endo TA; Koseki H; Shimojo N; Ohira M; Kamijo T
Oncotarget; 2017 Jul; 8(28):45046-45059. PubMed ID: 28620148
[TBL] [Abstract][Full Text] [Related]
8.
Maeshima R; Moulding D; Stoker AW; Hart SL
Nucleic Acid Ther; 2020 Aug; 30(4):237-248. PubMed ID: 32240058
[TBL] [Abstract][Full Text] [Related]
9. Dyngo-4a Induces Neuroblastoma Cell Differentiation Through The AKT and ERK1/2 Pathway.
Huang J; Zhou Y; Zeng S; Xu J; Liu L; Grothusen J; Liu R
CNS Neurol Disord Drug Targets; 2023; 22(10):1526-1534. PubMed ID: 36476431
[TBL] [Abstract][Full Text] [Related]
10. The deubiquitinating enzyme UCHL1 is a favorable prognostic marker in neuroblastoma as it promotes neuronal differentiation.
Gu Y; Lv F; Xue M; Chen K; Cheng C; Ding X; Jin M; Xu G; Zhang Y; Wu Z; Zheng L; Wu Y
J Exp Clin Cancer Res; 2018 Oct; 37(1):258. PubMed ID: 30359286
[TBL] [Abstract][Full Text] [Related]
11. Bi-modal differentiation pattern in a new human neuroblastoma cell line in vitro.
Matsushima H; Bogenmann E
Int J Cancer; 1992 May; 51(2):250-8. PubMed ID: 1568793
[TBL] [Abstract][Full Text] [Related]
12. CHAF1A Blocks Neuronal Differentiation and Promotes Neuroblastoma Oncogenesis via Metabolic Reprogramming.
Tao L; Moreno-Smith M; Ibarra-García-Padilla R; Milazzo G; Drolet NA; Hernandez BE; Oh YS; Patel I; Kim JJ; Zorman B; Patel T; Kamal AHM; Zhao Y; Hicks J; Vasudevan SA; Putluri N; Coarfa C; Sumazin P; Perini G; Parchem RJ; Uribe RA; Barbieri E
Adv Sci (Weinh); 2021 Oct; 8(19):e2005047. PubMed ID: 34365742
[TBL] [Abstract][Full Text] [Related]
13. ZNF281 inhibits neuronal differentiation and is a prognostic marker for neuroblastoma.
Pieraccioli M; Nicolai S; Pitolli C; Agostini M; Antonov A; Malewicz M; Knight RA; Raschellà G; Melino G
Proc Natl Acad Sci U S A; 2018 Jul; 115(28):7356-7361. PubMed ID: 29941555
[TBL] [Abstract][Full Text] [Related]
14. ARID1A-SIN3A drives retinoic acid-induced neuroblastoma differentiation by transcriptional repression of TERT.
Bui CB; Le HK; Vu DM; Truong KD; Nguyen NM; Ho MAN; Truong DQ
Mol Carcinog; 2019 Nov; 58(11):1998-2007. PubMed ID: 31365169
[TBL] [Abstract][Full Text] [Related]
15. Nucleolar protein PES1 is a marker of neuroblastoma outcome and is associated with neuroblastoma differentiation.
Nakaguro M; Kiyonari S; Kishida S; Cao D; Murakami-Tonami Y; Ichikawa H; Takeuchi I; Nakamura S; Kadomatsu K
Cancer Sci; 2015 Mar; 106(3):237-43. PubMed ID: 25557119
[TBL] [Abstract][Full Text] [Related]
16. Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma.
Weng Z; Lin J; He J; Gao L; Lin S; Tsang LL; Zhang H; He X; Wang G; Yang X; Zhou H; Zhao H; Li G; Zou L; Jiang X
Neuro Oncol; 2022 Jun; 24(6):872-885. PubMed ID: 34655293
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro.
Ora I; Bondesson L; Jönsson C; Ljungberg J; Pörn-Ares I; Garwicz S; Pâhlman S
Biochem Biophys Res Commun; 2000 Oct; 277(1):179-85. PubMed ID: 11027660
[TBL] [Abstract][Full Text] [Related]
18. Calreticulin regulates MYCN expression to control neuronal differentiation and stemness of neuroblastoma.
Lee AC; Shih YY; Zhou F; Chao TC; Lee H; Liao YF; Hsu WM; Hong JH
J Mol Med (Berl); 2019 Mar; 97(3):325-339. PubMed ID: 30612140
[TBL] [Abstract][Full Text] [Related]
19. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
Yang XH; Tang F; Shin J; Cunningham JM
BMC Syst Biol; 2017 Oct; 11(Suppl 5):92. PubMed ID: 28984200
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide induces the differentiation of retinoic acid-resistant neuroblastoma cells via upregulation of HoxC9.
Li C; Feng C; Chen Y; Wu P; Li P; Xiong X; Peng X; Wang Z; Li Y
Adv Clin Exp Med; 2022 Aug; 31(8):903-911. PubMed ID: 35467087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]